4.06
+0.11(+2.78%)
Currency In USD
Address
4000 Shoreline Court
South San Francisco, CA 94080
United States of America
Phone
650 822 5600
Sector
Healthcare
Industry
Biotechnology
Employees
55
First IPO Date
June 21, 2018
| Name | Title | Pay | Year Born |
| Dr. Christopher J. Kirk Ph.D. | Co-Founder, Chief Executive Officer & Director | 927,300 | 1972 |
| Mr. John Franklin Fowler | Co-Founder & Director | 57,037 | 1972 |
| Mr. Mark Schiller | Chief Legal Officer | 637,985 | 1980 |
| Mr. Marc L. Belsky CPA | Chief Financial Officer & Secretary | 653,208 | 1955 |
| Ms. Pattie Chiang | Principal Accounting Officer, Senior Vice President & Corporate Controller | 0 | 1962 |
| Mr. Zung To | Senior Vice President of Clinical Development | 0 | N/A |
| Mr. Joe Tedrick | Vice President of Human Resources | 0 | N/A |
| Dr. Jack Taunton Ph.D. | Co-Founder | 0 | N/A |
| Dr. Neel K. Anand Ph.D. | Senior Vice President of Research & Drug Discovery | 0 | N/A |
| Ms. Gitanjali Jain | Senior Vice President of Investor Relations & External Affairs | 0 | N/A |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.